In 2018, a phase II study (NCT03563716), evaluating the safety and efficacy of the anti-TIGIT mAb tiragolumab (MTIG7192A) plus atezolizumab in chemotherapy-naive patients with advanced PD-L1-selected NSCLC, was started. The gene discussed is CD274; the disease is non-small cell lung carcinoma.